Marc Turner: VETERANSFirst, CHAMPION-AF Trial, and HI-PEITHO Trial Driving Innovation at ACC26
Marc Turner, SVP for US Corporate Accounts and Healthcare Solutions at Boston Scientific, shared on LinkedIn:
”ACC26 this past weekend put a spotlight on the progress happening across cardiovascular care.
The data was an important part of that, but so was the collaboration and effort behind it. For Boston Scientific, a few events especially stood out.
CHAMPION‑AF Trial
Adherence to anticoagulation remains a real-world challenge, and that can increase stroke risk for patients with non-valvular AF.
That is why the new CHAMPION-AF data presented at ACC and published in NEJM is so meaningful.
The CHAMPION‑AF trial met all primary and secondary safety and efficacy endpoints, studying WATCHMAN™ as a first‑line option for stroke risk reduction.
Pending regulatory, guideline, and coverage updates, these findings could triple the eligible WATCHMAN population and expand how we think about stroke risk reduction in AF.
Read the press release.
HI‑PEITHO Trial
EKOS Endovascular System plus anticoagulation (AC) demonstrated superiority to AC alone for the treatment of patients with intermediate-risk PE.
In urgent situations, every minute matters. It is great to see technology make a meaningful difference when clinicians need to act quickly and confidently.
Read the press release.
VETERANSFirst
One moment that particularly stood out at ACC 2026 was the first-ever VETERANS First Panel, which challenged us to think differently about AFib care for our nation’s Veterans.
In resource-strained environments, barriers like medication adherence, fall risk, limited staffing, anesthesia availability, and travel burden can make traditional care pathways difficult.
The panel’s message was clear.
When we think differently, we expand access to stroke risk reduction and become catalysts for innovation in AFib care delivery.
I’m proud of the teams behind this work and grateful for the trust our customers and clinical partners place in us.
There is still more to do, but weekends like this are a strong reminder of what is possible when innovation stays grounded in patient needs.”
Stay updated with Hemostasis Today.
-
May 22, 2026, 14:50Eric Topol: New Nature Editorial on the Limits and Promise of AI Scientists
-
May 22, 2026, 14:40Harry Spoelstra: Omicron COVID-19 and Coronary Thrombosis Without Atherosclerosis
-
May 22, 2026, 14:21Clinical Challenges in Thrombosis III – Thrombosis Canada
-
May 22, 2026, 14:03Wolfgang Miesbach: Exploring the Role of Micronutrients in Healthy Longevity
-
May 22, 2026, 13:53Masoabi Sefojane: The Structural Invisibility of Bleeding Disorders in the Global South
-
May 22, 2026, 13:41Ney Carter Borges: New Trial Highlights IVL as Effective Strategy for Calcified Coronary Lesions
-
May 22, 2026, 13:36Ajay Samkaria։ A Compatible Crossmatch Does Not Always Mean Complete Safety
-
May 22, 2026, 13:31Mariam Swidan: Why Hemolysis Severity Matters in G6PD Deficiency
-
May 22, 2026, 13:25Augustina Isioma Ikusemoro: Why Plasma and RBC Transfusions Follow Different Compatibility Rules